Science and Research

A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS-COV-2 (EU-COVAT-1_AGED)

Rate of 2-fold antibody titre increase 14 days after a 4th vaccination dose measured by quantitative enzyme-linked immunosorbent assay (Anti-
RBD-ELISA) against wildtype virus.

Study details
Study-ID: 2021-004526-29
Study-ID: 2021-004526-29
DZL Disease Area: PALI
DZL Disease Area: PALI
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - public
Funding: Externally - public
DZL Participating Sites: BREATH
DZL Participating Sites: BREATH
Start Date: 08.07.2022
Completion Date: 01.12.2023
Status: Closed
Status: Closed
DZL recruiting center


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.